ENTITY

Oncopeptides (ONCO SS)

18
Analysis
Health Care • Sweden
Oncopeptides AB is a biotech company that engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases. The company's lead product is Pepaxti (melflufen), a peptide-drug conjugate for the treatment of relapsed or refractory multiple myeloma. Oncopeptides' proprietary Peptide Drug Conjugate (PDC) platform is designed to rapidly and selectively deliver cytotoxic agents into cancer cells.
more
Company Presentation • 12 Oct 2026 14:00

Study update

Company Presentation • 24 Jan 2022 23:57

FDA Announcement

Company Presentation • 22 Oct 2021 08:00

Status Update

Company Presentation • 27 Aug 2026 15:00

Q2 2026

Company Presentation • 17 Mar 2026 16:00

Life Science Conference 2026

x